Levosimendan en es it fr

Levosimendan Brand names, Levosimendan Analogs

Levosimendan Brand Names Mixture

  • Alphasel tablets (calcium phosphate [dibasic] + cobalt sulfate + D-alpha tocopheryl acetate + selenium sulfide)
  • Previte (neomycin sulfate + selenium sulfide + streptomycin sulfate + vitamin A + vitamin D + vitamin E + vitamin K1)

Levosimendan Chemical_Formula


Levosimendan RX_link

No information avaliable

Levosimendan fda sheet

Levosimendan msds (material safety sheet)

Levosimendan MSDS

Levosimendan Synthesis Reference

No information avaliable

Levosimendan Molecular Weight

280.285 g/mol

Levosimendan Melting Point

No information avaliable

Levosimendan H2O Solubility

No information avaliable

Levosimendan State


Levosimendan LogP


Levosimendan Dosage Forms

Intravenous (loading dose of 12 to 24 micrograms/kg over 10 minutes followed by a continuous infusion of 0.05 to 0.2 micrograms/kg per minute, adjusted according to response)

Levosimendan Indication

For short term treatment of acutely decompensated severe chronic heart failure (CHF).

Levosimendan Pharmacology

Levosimendan is a new Ca2+-sensitizing inotropic agent. Ca2+ sensitizers represent a new class of inotropic agents, which overcome the disadvantages associated with currently available inotropic agents in as they are not associated with an increased risk of arrhythmias, cell injury and death due to Ca2+ overload in myocardial cells; they do not increase the activation energy; and they have the potential to reverse contractile dysfunction under pathophysiologic conditions, such as acidosis or myocardial stunning. Levosimendan has not been approved for use in the U.S. or Canada.

Levosimendan Absorption

The bioavailability of oral levosimendan is 85 ± 6% in healthy volunteers and 84 ± 4% in patients.

Levosimendan side effects and Toxicity

No information avaliable

Levosimendan Patient Information

No information avaliable

Levosimendan Organisms Affected

Humans and other mammals